Preferential PDE4B Inhibition - A Step toward a New Treatment for Idiopathic Pulmonary Fibrosis.

[1]  T. Wynn,et al.  Fibrosis: from mechanisms to medicines , 2020, Nature.

[2]  M. Kool,et al.  Inflammation and immunity in IPF pathogenesis and treatment. , 2019, Respiratory medicine.

[3]  S. Field,et al.  Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD , 2010, Drug design, development and therapy.

[4]  D. Aronoff,et al.  Prostaglandin E(2) inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[5]  Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. , 2015, The New England journal of medicine.

[6]  M. Rubin.  Response 4. , 1997, Journal of lower genital tract disease.